trinity biotech - 500 Beiträge pro Seite
eröffnet am 18.02.00 17:56:39 von
neuester Beitrag 22.02.00 23:07:31 von
neuester Beitrag 22.02.00 23:07:31 von
Beiträge: 10
ID: 66.020
ID: 66.020
Aufrufe heute: 0
Gesamt: 889
Gesamt: 889
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 4 Minuten | 14348 | |
| vor 11 Minuten | 3017 | |
| vor 3 Minuten | 2739 | |
| heute 11:45 | 2013 | |
| vor 3 Minuten | 1323 | |
| vor 18 Minuten | 1118 | |
| vor 4 Minuten | 963 | |
| vor 45 Minuten | 765 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.187,17 | +0,14 | 221 | |||
| 2. | 2. | 151,76 | +12,17 | 201 | |||
| 3. | 8. | 9,5800 | -33,98 | 153 | |||
| 4. | 5. | 0,0313 | +95,63 | 41 | |||
| 5. | 9. | 747,90 | +5,03 | 41 | |||
| 6. | 3. | 0,1995 | +4,45 | 39 | |||
| 7. | 12. | 19,300 | -1,08 | 33 | |||
| 8. | 6. | 42,60 | -2,96 | 31 |
Feedback
Trinity biotech jetzt schon 12,98%
und das ist es der anfang
und das ist es der anfang
Ganz deiner meinung...
Habe schön des öfteren am Board trinity gelobt.
Aber irgendwie warten wieder alle ab und verpassen dabei den Zug.
Mein Tip bleibt, daß trinity sich locker verdreifachen kann.
Kauft jetzt oder später, letztendlich muß aber Trinity in jedem wachstrumsorientierten Depot sein.
Habe schön des öfteren am Board trinity gelobt.
Aber irgendwie warten wieder alle ab und verpassen dabei den Zug.
Mein Tip bleibt, daß trinity sich locker verdreifachen kann.
Kauft jetzt oder später, letztendlich muß aber Trinity in jedem wachstrumsorientierten Depot sein.
ist drin :-)
zu 4,20......10-15 sind locker drin in 4-8 wochen...
nautilus
zu 4,20......10-15 sind locker drin in 4-8 wochen...
nautilus
Ist in meinem Depot auch drin :-))
zu 4.63
Hexenzauber
zu 4.63
Hexenzauber
In meinem Depot sind sie auch schon drin ,jetzt müssen wir nur noch
ein paar lange Artikel schreiben.
Hier ist die aktuelle Pressemitteilung:
TRINITY BIOTECH ANNOUNCES RECORD
YEAR END RESULTS
74% Increase in Profit before exceptional items and
60% Rise in EPS before exceptional items for year
Dublin, Ireland (February 8, 2000) . . . .Trinity Biotech plc (NASDAQ: TRIBY) today announced record results for the three months and year ended December 31, 1999.
For the year ended December 31, 1999, the Company reported a profit before exceptional items of $4,511,000 or US$0.16 per share compared to a profit before exceptional items of $2,588,000 or US$0.10 per share for the year ended December 31, 1998. This represents a 74% growth in profit before exceptional items and a 60% growth in earnings per share before exceptional items.
During the last quarter, the Company reported two exceptional items netting to an exceptional profit of $404,000.These relate to the profit on the sale of the Dublin factory ($1,014,000) and the write down of an investment ($610,000) and represent $0.014 per share.The net profit after exceptional items rises to $4,916,000 with earnings per share at $0.175 per share.Fiscal 1999 revenues increased by 13% to $26,105,000 from $23,170,000.However, when one excludes the low margin Warner Lambert pregnancy business, which Trinity disposed of in the prior year, the revenue has grown by 49%.For the three months ended December 31, 1999, revenues rose 6% to $6,650,000 from $6,301,000 for the same period last year.Profit before exceptional items for the quarter increased 48% to $1,298,000, which compares to $876,000 for the same period last year.
Commenting on the results, Jonathan O’Connell, Chief Financial Officer said, “Fiscal 1999 was an excellent year for Trinity Biotech.The company increased its profit before exceptional items by 74% and its earnings per share by over 60%.When one excludes the amortization of goodwill, profits increased by over 94%. During the year, Trinity successfully consolidated the acquisitions it made during 1998 and has resulted in substantial improvement in our operating results. The Company’s gross margin has improved significantly from 35% to 44% for the year and from 37% to 49% for the quarter.
The Company’s sale and leaseback transaction and new financing has significantly strengthened the Company’s balance sheet.The sale and leaseback and the new financing reduced our net debt significantly from $25mm at the beginning of 1999 down to $13.6mm at the end of 1999.The Company’s debt-to-equity ratio stands at an undemanding 59% compared to 157% one year ago.
The Company now has cash of over $3mm and total assets of over $44mm.
Trinity Biotech develops, manufactures, and markets over 100 diagnostic products for the point-of-care (POC), self-testing (OTC), and clinical laboratory segments of the diagnostic market.Trinity sells worldwide in over 80 countries through 280 international distributors and strategic partners.
ein paar lange Artikel schreiben.
Hier ist die aktuelle Pressemitteilung:
TRINITY BIOTECH ANNOUNCES RECORD
YEAR END RESULTS
74% Increase in Profit before exceptional items and
60% Rise in EPS before exceptional items for year
Dublin, Ireland (February 8, 2000) . . . .Trinity Biotech plc (NASDAQ: TRIBY) today announced record results for the three months and year ended December 31, 1999.
For the year ended December 31, 1999, the Company reported a profit before exceptional items of $4,511,000 or US$0.16 per share compared to a profit before exceptional items of $2,588,000 or US$0.10 per share for the year ended December 31, 1998. This represents a 74% growth in profit before exceptional items and a 60% growth in earnings per share before exceptional items.
During the last quarter, the Company reported two exceptional items netting to an exceptional profit of $404,000.These relate to the profit on the sale of the Dublin factory ($1,014,000) and the write down of an investment ($610,000) and represent $0.014 per share.The net profit after exceptional items rises to $4,916,000 with earnings per share at $0.175 per share.Fiscal 1999 revenues increased by 13% to $26,105,000 from $23,170,000.However, when one excludes the low margin Warner Lambert pregnancy business, which Trinity disposed of in the prior year, the revenue has grown by 49%.For the three months ended December 31, 1999, revenues rose 6% to $6,650,000 from $6,301,000 for the same period last year.Profit before exceptional items for the quarter increased 48% to $1,298,000, which compares to $876,000 for the same period last year.
Commenting on the results, Jonathan O’Connell, Chief Financial Officer said, “Fiscal 1999 was an excellent year for Trinity Biotech.The company increased its profit before exceptional items by 74% and its earnings per share by over 60%.When one excludes the amortization of goodwill, profits increased by over 94%. During the year, Trinity successfully consolidated the acquisitions it made during 1998 and has resulted in substantial improvement in our operating results. The Company’s gross margin has improved significantly from 35% to 44% for the year and from 37% to 49% for the quarter.
The Company’s sale and leaseback transaction and new financing has significantly strengthened the Company’s balance sheet.The sale and leaseback and the new financing reduced our net debt significantly from $25mm at the beginning of 1999 down to $13.6mm at the end of 1999.The Company’s debt-to-equity ratio stands at an undemanding 59% compared to 157% one year ago.
The Company now has cash of over $3mm and total assets of over $44mm.
Trinity Biotech develops, manufactures, and markets over 100 diagnostic products for the point-of-care (POC), self-testing (OTC), and clinical laboratory segments of the diagnostic market.Trinity sells worldwide in over 80 countries through 280 international distributors and strategic partners.
Trading Spotlight
!
Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an feedback@wallstreet-online.de
bei vcall.com gibt es ein real audio earnings call -- ist sehr interessant.
Dieses Board gefällt mir Super-früher oder später(höchstens 2 Tage)
findet man zu jeder interessanten Aktie einen Thread.
Bin bei 4,70 rein...die kommt!!!
So Long
findet man zu jeder interessanten Aktie einen Thread.
Bin bei 4,70 rein...die kommt!!!
So Long
Jetzt 7,oo !!
Habe am Freitag für 4.20 verkauft und bin heute für 5.70 wieder
eingestiegen. Meine Bank hatte zwar meine Verkaufsorder 6 Minuten
vor Börsenerhöffnung gestrichen, daß hatte aber nicht genügt. 22 TDM
Schaden sind mir dadurch entstanden.
eingestiegen. Meine Bank hatte zwar meine Verkaufsorder 6 Minuten
vor Börsenerhöffnung gestrichen, daß hatte aber nicht genügt. 22 TDM
Schaden sind mir dadurch entstanden.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 221 | ||
| 201 | ||
| 153 | ||
| 41 | ||
| 41 | ||
| 39 | ||
| 33 | ||
| 31 | ||
| 30 | ||
| 28 |
| Wertpapier | Beiträge | |
|---|---|---|
| 28 | ||
| 28 | ||
| 26 | ||
| 25 | ||
| 24 | ||
| 23 | ||
| 23 | ||
| 20 | ||
| 18 | ||
| 17 |
